CAR-T therapy survivors monitored for Long-Term safety and survival

NCT ID NCT06906380

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows up to 49 people with relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who previously received ARD103 CAR-T cell therapy in an earlier trial. Researchers will track side effects, overall survival, and how long any response lasts. The goal is to better understand the long-term safety and effectiveness of this treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA, IN RELAPSE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute myeloid leukemia myelodysplastic syndrome myelodysplastic syndrome with excess blasts

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • MD Anderson Cancer Center

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Novant Health Cancer Institute

    Charlotte, North Carolina, 28204, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Novant Health Cancer Institute

    Winston-Salem, North Carolina, 27201, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••